J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug

Johnson & Johnson has paused enrollment in the Phase 2b trial of its Alzheimer’s disease candidate, and the stock {$ACIU} of its partner AC Immune closed down about 10% on Wednesday. The asset is an ...